In Vitro Assessment of CYP Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate
Kinsenoside, the herb derived medicine isolated from the plant Anoect chilus, has diverse pharmacological actions, and it is considered to be a promising antihyperlipidemic drug candidate. This study evaluates the effects of kinsenoside on CYP enzyme mediated drug metabolism in order to predict the potential for kinsenoside drug interactions. Kinsenoside was tested at different concentrations of 0.1, 0.3, 1, 3, 10, 30, and 100 uM in human liver microsomes. The c Cktail probe assay based on liquid chromatography tandem mass spectrometry was conducted to measure the CYP inhibitory effect of kinsenoside. Subsequently, the metabolism profiles of amlodipine and lovastatin in human liver microsomes were analyzed following co incubation with kinsenoside. The concentration levels of the parent drug and the major metabolites were compared with the kinsenoside cotreated samples. The effect of kinsenoside was negligible on the enzyme activity of all the CYP isozymes tested even though CYP2A6 was slightly inhibited at higher concentrations. The drug drug interaction assay also showed that the concomitant use of kinsenoside has a non significant effect on the concentration of lovastatin or amlodipine, and their major metabolites. So, it was concluded that there is almost no risk of drug interaction between kinsenoside and CYP drug substrates via CYP inhibition.
Molecules